Symptomatic Dermographism: 29% Response Drives Remibrutinib Label Expansion

Novartis announced on October 7, 2026, the FDA has approved Rhapsido (remibrutinib), an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor, for adults with symptomatic dermographism (SD) whose disease is inadequately controlled by H1 antihistamines.¹ Remibrutinib is the first treatment approved specifically for SD, a form of chronic inducible urticaria in which hives and itch are triggered by everyday skin friction, scratching, or rubbing.

The decision comes just over a year after FDA approved the drug for chronic spontaneous urticaria (CSU) in adults who remain symptomatic on H1 antihistamines.¹ More than 90% of adults with chronic hives have either CSU or SD, and remibrutinib is now the only prescription therapy approved for both when antihistamines alone do not control symptoms.

What Did the RemIND Trial Show?

The approval is based on the SD cohort of the Phase III RemIND trial, which enrolled patients who remained symptomatic on second-generation H1 antihistamines.¹ At Week 12, 29.3% of patients treated with remibrutinib achieved a complete response from hives, as measured by the Total Fric Score, versus 14.0% of patients receiving placebo (p=0.0229). Responses were seen as early as Week 2.

Through Week 24, the safety profile in SD was consistent with that observed in CSU.¹ The most common adverse events, occurring at an incidence of 3% or greater, were nasopharyngitis, bleeding, headache, nausea, and abdominal pain. No routine laboratory monitoring is required.

"SD is a chronic, debilitating condition with historically limited treatment options," said Giselle Mosnaim, MD, MS, clinical professor, the University of Chicago Pritzker School of Medicine, and lead RemIND trial investigator, said in a press release.¹ "Remibrutinib offers, for the first time, an approach to treatment specifically for SD patients who remain inadequately controlled with H1 antihistamines alone, representing a meaningful step forward for this population."

RemIND also evaluated remibrutinib in cold urticaria and cholinergic urticaria, and Novartis plans to submit the full dataset to health authorities globally where appropriate.¹

"For people living with SD, seemingly routine contact with the skin can trigger hives and itch," said Lindsey Finklea, MD, an adjunct professor, University of Texas, and RemIND trial investigator, said in the press release.¹ "Having the first FDA-approved medicine specifically for SD marks an important change in how clinicians can approach care and offers renewed hope for patients whose symptoms are not adequately controlled by H1 antihistamines."

Why Does This Approval Matter?

The approval illustrates a lifecycle approach in which a single Phase III study with multiple disease cohorts supports sequential label expansions for an already-marketed small molecule.¹ Because the new indication extends an existing oral tablet rather than introducing a new formulation or dosage strength, the regulatory emphasis falls on clinical evidence rather than new process development. Each added indication, however, raises the stakes for demand forecasting and supply continuity.

The safety findings also carry weight across the drug class.¹ BTK inhibitors are best established as blood cancer drugs, and several autoimmune candidates have failed pivotal trials, while liver toxicity has complicated development of some drugs in the class. Novartis recently reported positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple sclerosis, where remibrutinib reduced annualized relapse rates versus teriflunomide with no liver safety signals.² The molecule is also being studied in hidradenitis suppurativa and food allergy.

If those programs succeed, a growing share of patients across dermatology, allergy, and neurology would draw on a single oral solid dose supply chain.² That growth coincides with Novartis's broader US manufacturing buildout. In April 2026, the company announced plans for a facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient manufacturing for solid dosage tablets, capsules, and RNA therapeutics, its seventh new facility under a $23 billion investment in US-based manufacturing and R&D.³

References

1. Novartis. Novartis Rhapsido (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU). Press release. October 7, 2026. Accessed October 7, 2026. https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu
2. Novartis. Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials. Press release. Sept. 1, 2026. Accessed October 7, 2026. https://www.novartis.com/news/media-releases/novartis-remibrutinib-high-efficacy-oral-btk-inhibitor-significantly-reduces-relapse-rates-and-shows-favorable-safety-profile-phase-iii-rms-trials
3. Novartis. Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility. Press release. April 30, 2026. Accessed October 7, 2026. https://www.novartis.com/news/media-releases/novartis-finalizes-us-manufacturing-and-rd-expansion-plan-seventh-new-facility